There is a moment in 2009 that, in hindsight, changed the trajectory of modern medicine. Derrick Rossi, a stem cell biologist at Harvard Medical School, was working late in his lab on a problem that had fascinated — and frustrated — scientists for decades: how to reprogram adult human cells to behave like embryonic stem […]
The Untold Story of Moderna: From a Harvard Lab to the Arms of Billions Read More »
The FDA doesn’t always say no with a single word — sometimes it sends a letter. But for Watertown-based Disc Medicine, the Complete Response Letter it received this month for its lead drug bitopertin had the same effect: a hard stop that forced the company to rethink its near-term future, and to part ways with
Disc Medicine Cuts One in Five Jobs After FDA Rejects Bitopertin Application Read More »
There is a stretch of Cambridge, Massachusetts — barely a square mile in size — that has quietly become the most consequential piece of real estate in global science. On any given morning, the Red Line deposits researchers, entrepreneurs, venture capitalists, and executives from companies like Moderna, Biogen, Google, and Takeda onto the same sidewalks.
The Kendall Square Effect: The Most Valuable Square Mile in Science Read More »
In the high-stakes world of metabolic health, the next frontier isn’t a more effective injection—it’s a pill. As of late February 2026, two Boston-based startups, Vivtex and Nimbus Therapeutics, have emerged as the vanguard in the race to disrupt the $100 billion obesity market dominated by giants like Novo Nordisk and Eli Lilly. This week’s
